Anifrolumab (unblinded, open label)
Sponsors
AstraZeneca
Conditions
Polymyositis, DermatomyositisSclerodermaSystemic Sclerosis
Phase 3
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
Active, not recruitingNCT05925803
Start: 2023-11-08End: 2028-04-05Updated: 2026-09-10
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
RecruitingNCT06455449
Start: 2024-06-20End: 2028-08-04Target: 240Updated: 2026-05-28